A Prospective Randomized Controlled Study on Adjuvant Transarterial Chemoembolization (TACE) Before and After Surgery for Long-term Prognosis in Patients with Multinodular Hepatocellular Carcinoma.

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2500114730

Enrollment

Unknown

Registered

2025-12-17

Start date

2026-01-01

Completion date

Unknown

Last updated

2026-01-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hepatocellular carcinoma

Interventions

Control group:Postoperative TACE (treatment)

Test group:Perioperative TACE (treatment)

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: Aged between 18 and 80 years; no prior systemic therapy; newly diagnosed with or intraoperatively identified as having multinodular hepatocellular carcinoma, classified as CNLC stage Ib or IIa; initial treatment comprising surgical resection or transarterial chemoembolisation followed by surgery; Child–Pugh grade A or B; no other treatment administered prior to confirmed recurrence.

Exclusion criteria

Exclusion criteria: Imaging findings suggestive of vascular invasion or extrahepatic metastasis. Contraindications to hepatectomy. Poor postoperative liver function precluding tolerance to interventional therapy.

Design outcomes

Primary

Measure	Time frame
2 year DFS;	—

Secondary

Measure	Time frame
2 year OS;30-day postoperative complication rate;	—

Countries

China

Contacts

Public ContactJiang Li

West China Hospital of Sichuan University

jl339@126.com+86 189 8060 6338

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026